Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

H. Kamijuku, Y. Nagata, X. Jiang, T. Ichinohe, T. Tashiro, K. Mori, M. Taniguchi, Kouji Hase, H. Ohno, T. Shimaoka, S. Yonehara, T. Odagiri, M. Tashiro, T. Sata, H. Hasegawa, K. I. Seino

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

Original languageEnglish
Pages (from-to)208-218
Number of pages11
JournalMucosal Immunology
Volume1
Issue number3
DOIs
Publication statusPublished - 2008 May
Externally publishedYes

Fingerprint

Cross Protection
Galactosylceramides
Natural Killer T-Cells
Orthomyxoviridae
Nose
Nasal Mucosa
Vaccination
Vaccines
Influenza Vaccines
Interleukin-4
Dendritic Cells
Immunoglobulin A
Fluorescence

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. / Kamijuku, H.; Nagata, Y.; Jiang, X.; Ichinohe, T.; Tashiro, T.; Mori, K.; Taniguchi, M.; Hase, Kouji; Ohno, H.; Shimaoka, T.; Yonehara, S.; Odagiri, T.; Tashiro, M.; Sata, T.; Hasegawa, H.; Seino, K. I.

In: Mucosal Immunology, Vol. 1, No. 3, 05.2008, p. 208-218.

Research output: Contribution to journalArticle

Kamijuku, H, Nagata, Y, Jiang, X, Ichinohe, T, Tashiro, T, Mori, K, Taniguchi, M, Hase, K, Ohno, H, Shimaoka, T, Yonehara, S, Odagiri, T, Tashiro, M, Sata, T, Hasegawa, H & Seino, KI 2008, 'Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses', Mucosal Immunology, vol. 1, no. 3, pp. 208-218. https://doi.org/10.1038/mi.2008.2
Kamijuku, H. ; Nagata, Y. ; Jiang, X. ; Ichinohe, T. ; Tashiro, T. ; Mori, K. ; Taniguchi, M. ; Hase, Kouji ; Ohno, H. ; Shimaoka, T. ; Yonehara, S. ; Odagiri, T. ; Tashiro, M. ; Sata, T. ; Hasegawa, H. ; Seino, K. I. / Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. In: Mucosal Immunology. 2008 ; Vol. 1, No. 3. pp. 208-218.
@article{c39d4bbba397440aafaccd5e63187823,
title = "Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses",
abstract = "In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.",
author = "H. Kamijuku and Y. Nagata and X. Jiang and T. Ichinohe and T. Tashiro and K. Mori and M. Taniguchi and Kouji Hase and H. Ohno and T. Shimaoka and S. Yonehara and T. Odagiri and M. Tashiro and T. Sata and H. Hasegawa and Seino, {K. I.}",
year = "2008",
month = "5",
doi = "10.1038/mi.2008.2",
language = "English",
volume = "1",
pages = "208--218",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

AU - Kamijuku, H.

AU - Nagata, Y.

AU - Jiang, X.

AU - Ichinohe, T.

AU - Tashiro, T.

AU - Mori, K.

AU - Taniguchi, M.

AU - Hase, Kouji

AU - Ohno, H.

AU - Shimaoka, T.

AU - Yonehara, S.

AU - Odagiri, T.

AU - Tashiro, M.

AU - Sata, T.

AU - Hasegawa, H.

AU - Seino, K. I.

PY - 2008/5

Y1 - 2008/5

N2 - In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

AB - In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

UR - http://www.scopus.com/inward/record.url?scp=42149161737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149161737&partnerID=8YFLogxK

U2 - 10.1038/mi.2008.2

DO - 10.1038/mi.2008.2

M3 - Article

C2 - 19079180

AN - SCOPUS:42149161737

VL - 1

SP - 208

EP - 218

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 3

ER -